###begin article-title 0
Pathogenic Mitochondrial DNA Mutations Are Common in the General Population
###end article-title 0
###begin p 1
This document may be redistributed and reused, subject to .
###end p 1
###begin p 2
###xml 738 744 <span type="species:ncbi:9606">humans</span>
Mitochondrial DNA (mtDNA) mutations are a major cause of genetic disease, but their prevalence in the general population is not known. We determined the frequency of ten mitochondrial point mutations in 3168 neonatal-cord-blood samples from sequential live births, analyzing matched maternal-blood samples to estimate the de novo mutation rate. mtDNA mutations were detected in 15 offspring (0.54%, 95% CI = 0.30-0.89%). Of these live births, 0.00107% (95% CI = 0.00087-0.0127) harbored a mutation not detected in the mother's blood, providing an estimate of the de novo mutation rate. The most common mutation was m.3243A-->G. m.14484T-->C was only found on sub-branches of mtDNA haplogroup J. In conclusion, at least one in 200 healthy humans harbors a pathogenic mtDNA mutation that potentially causes disease in the offspring of female carriers. The exclusive detection of m.14484T-->C on haplogroup J implicates the background mtDNA haplotype in mutagenesis. These findings emphasize the importance of developing new approaches to prevent transmission.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 136 139 124 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;6</sup>
###xml 136 139 124 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1 bib2 bib3 bib4 bib5 bib6" ref-type="bibr"><sup>1&#8211;6</sup></xref>
###xml 679 680 667 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 679 680 667 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib7" ref-type="bibr"><sup>7</sup></xref>
###xml 795 796 783 784 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 795 796 783 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib8" ref-type="bibr"><sup>8</sup></xref>
###xml 1108 1109 1096 1097 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 1108 1109 1096 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib8" ref-type="bibr"><sup>8</sup></xref>
###xml 1572 1573 1560 1561 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sup>
###xml 1572 1573 1560 1561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib9" ref-type="bibr"><sup>9</sup></xref>
Disease-based epidemiological studies provide estimates of the minimum population prevalence of mtDNA disease as approximately1 in 5000,1-6 but the incidence of new mutations and the frequency of asymptomatic carriers have not been fully established. Fundamental differences between mtDNA inheritance and the Mendelian system mean that de novo mutation rates and carrier frequencies cannot be deduced with a standard Mendelian population-genetic approach. Strict maternal inheritance results in negligible intermolecular recombination apparent at the population level, and the presence of thousands of copies of mtDNA within each diploid mammalian cell adds a further complexity.7 Most pathogenic mtDNA mutations are heteroplasmic, with varying amounts of mutated mtDNA present within each cell.8 Phenotypic expression is ultimately dependent upon the proportion of mutated mtDNA or the amount of wild-type mtDNA within vulnerable tissues. This only leads to a biochemical defect of the respiratory chain when a critical threshold level is exceeded, with the precise amount varying from mutation to mutation.8 In keeping with this, a family with mitochondrial disease usually presents clinically for the first time when an individual inherits a high proportion of mutated mtDNA from a mother who harbors a low level of mutated mtDNA and remains asymptomatic. Such dramatic changes in heteroplasmy can occur in a single generation because of a restriction in the intracellular mtDNA content during embryonic development that is responsible for the mtDNA genetic bottleneck.9
###end p 4
###begin p 5
###xml 228 231 228 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;6</sup>
###xml 228 231 228 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1 bib2 bib3 bib4 bib5 bib6" ref-type="bibr"><sup>1&#8211;6</sup></xref>
Previous estimates of the carrier frequency of mtDNA mutations were largely based on the ascertainment of pedigrees through one or more clinically affected individuals, followed by careful family tracing of the maternal lineage.1-6 This raises the possibility that de novo mtDNA mutations remain undetected in the population because they are well below the threshold required for phenotypic expression or because they lie below the detection threshold of conventional sequencing. Many of these mutations would be lost through random genetic drift, causing disease only when the percentage level of mutation drifts upwards in one or more family members and exceeds the threshold required for clinical presentation.
###end p 5
###begin p 6
###xml 199 204 199 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10,11</sup>
###xml 199 204 199 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib10 bib11" ref-type="bibr"><sup>10,11</sup></xref>
A further complication is the strong association between specific pathogenic mtDNA mutations and closely related mtDNA polymorphisms (haplogroups), which is not thought to be due to a founder effect.10,11 However, it is not known whether the polymorphisms that define the haplogroup predispose it to de novo mutation events, whether they cause the preferential segregation of pathogenic mutations, or whether they affect clinical expression of the associated disorder. The only way of addressing these issues is by screening a large random sample of the population, with matched maternal samples, to determine whether the detected mutations are de novo or inherited.
###end p 6
###begin title 7
Material and Methods
###end title 7
###begin p 8
###xml 341 343 309 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sup>
###xml 341 343 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib12" ref-type="bibr"><sup>12</sup></xref>
###xml 720 722 688 690 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sup>
###xml 720 722 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib13" ref-type="bibr"><sup>13</sup></xref>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
We measured the frequency of the ten pathogenic mtDNA mutations often found in patients with mitochondrial disease (m.1555A-->G, m.3243A-->G, m.3460G-->A, m.7445A-->G, m.8344A-->G, m.8993T-->G, m.11778G-->A, m.13513G-->A, m.14459G-->A, m.14484T-->C) in approximately3000 sequential umbilical-cord-blood samples from north Cumbria in England.12 Consent for inclusion into the study exceeded 80%. Ethical approval to investigate mtDNA mutations within this cohort was granted by the West Cumbria Local Research Ethics Committee (Project 381). Previous epidemiological and nuclear genetic studies established that this cohort is a random sample of the population with numerous nuclear alleles in Hardy-Weinberg equilibrium.13
###end p 8
###begin title 9
Haplogroup Determination
###end title 9
###begin p 10
###xml 126 128 126 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib14" ref-type="bibr"><sup>14</sup></xref>
###xml 249 256 249 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl1" ref-type="table">Table 1</xref>
The ten major European mtDNA haplogroups were determined in 344 random samples from the cohort as described in the literature,14 with the use of modified primer sequences. This confirmed that the study group was representative of the UK population (Table 1). Mitochondrial haplogroups were also determined in samples that harbored mtDNA point mutations and in their mothers, with the same approach used.
###end p 10
###begin title 11
High-Throughput Genotyping
###end title 11
###begin p 12
###xml 1074 1075 1036 1037 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1934 1942 1866 1874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Table S1</xref>
The population was genotyped by primer extension of multiplex PCR products with the detection of the allele-specific extension products by matrix-associated laser desorption/ionization time of flight (MALDI-TOF; Sequenom MassARRAY, San Diego, CA). Assays were designed with Sequenom Assay Design software v2.0.7.0, resulting in five multiplex assays. The allelotyping assay was followed according to manufacturer's instructions, with modifications. At the primary PCR step, DNA was amplified under the following conditions: initial denaturation of 95degreesC for 15 minutes, then 30 cycles of denaturation at 95degreesC for 20 seconds, annealing at 60degreesC for 30 seconds, and extension at 72degreesC for 1 minute. Finally, there was a further extension at 72degreesC for 3 minutes before the samples were cooled and stored at 4degreesC. A homogeneous MassEXTEND (hME) reaction mix containing appropriate hME EXTEND mix (1x buffer with 0.225 mM d/ddNTPs), 2.7 muM MassEXTEND primer, and 0.576 U ThermoSequenase (GE Healthcare), made up to a final volume of 2 muL with anH2O, was added to each SAP-cleaned PCR product. The microplate was then thermocycled as follows: initial denaturation of 94degreesC for 2 minutes, then 55 cycles of denaturation at 94degreesC for 5 seconds, annealing at 52degreesC for 5 seconds, and extension at 72degreesC for 5 seconds before cooling to 4degreesC. The sample microplate and a 384 SpectroCHIP were loaded onto the deck of the Samsung Nanodispenser. 15 nL of solution from the sample microplate was transferred onto the chip, which was read by a Bruker Autoflex Mass Spectrometer system. Data was collected with the use of SpectroACQUIRE v3.3.1.3 software and visualised with the use of MassARRAY Typer v3.4 TyperAnalyzer software. The sensitivity of the MALDI-TOF MS assay for each mutation was assessed with mixed cloned mtDNA fragments in duplicate for both uniplex and multiplex reactions (Table S1, available online).
###end p 12
###begin p 13
###xml 127 135 125 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Table S1</xref>
The assay detected >/= 10% mutated mtDNA in each case, and for some mutations, the detection threshold was considerably lower (Table S1). For nine mutations, positive calls were confirmed by direct sequencing and last-cycle fluorescent PCR-RFLP from an independent aliquot of DNA, which established the percentage mutated mtDNA (see below). The m.1555A-->G mutation was confirmed by cloning and sequencing from a separate aliquot of DNA from the same subject.
###end p 13
###begin title 14
Measurement of mtDNA Heteroplasmy
###end title 14
###begin p 15
###xml 157 159 157 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">15</sup>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib15" ref-type="bibr"><sup>15</sup></xref>
###xml 445 453 443 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Table S2</xref>
Positive calls were confirmed in an independent aliquot from the original DNA sample with the use of last-cycle fluorescent PCR-RFLP as described previously.15 This also established the percentage mutated mtDNA. For the m.1555A-->G mutation, heteroplasmy was quantified by cloning and sequencing of 23 independent mtDNA fragments from an independent aliquot from the original DNA sample. Primers and restriction enzymes and digests are shown in Table S2.
###end p 15
###begin title 16
MtDNA Sequencing
###end title 16
###begin p 17
###xml 194 202 194 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Table S3</xref>
###xml 512 514 512 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">16</sup>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib16" ref-type="bibr"><sup>16</sup></xref>
The mitochondrial noncoding control region (D-loop) was sequenced by PCR of four overlapping segments, with the use of forward and reverse M13-tagged primer pairs. Primer sequences are shown in Table S3. PCR products were treated with ExoSAP (ExoSAP-IT, GE Healthcare, USA) and sequenced on a fluorescent genetic analyzer (Beckman-Coulter CEQ 8000) with the standard dideoxy chain-termination method (Beckman-Coulter Quickstart). The sequence data were compared to the revised Cambridge reference sequence (rCRS)16 with the use of CEQ Sequence Analysis v2.3.13 analysis software (Beckman-Coulter). This allowed identification of D-loop changes and comparison of positive samples.
###end p 17
###begin title 18
Statistical Analysis
###end title 18
###begin p 19
###xml 148 150 148 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">17</sup>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib17" ref-type="bibr"><sup>17</sup></xref>
###xml 228 230 228 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">18</sup>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib18" ref-type="bibr"><sup>18</sup></xref>
Frequencies were compared by calculation of empirical P-values with a Monte Carlo-based simulation approach based on the method of Roff and Bentzen.17 Exact 95% confidence intervals were calculated by the Clopper-Pearson method.18
###end p 19
###begin title 20
Results
###end title 20
###begin title 21
Population Prevalence
###end title 21
###begin p 22
###xml 127 134 127 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl2" ref-type="table">Table 2</xref>
###xml 676 696 664 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="sec2" ref-type="sec">Material and Methods</xref>
Known duplicate samples from the same individual were 100% concordant. mtDNA mutations were detected in 15 different subjects (Table 2), giving a total mean frequency of 0.54% for the ten mutations (95% CI = 0.30-0.89%) in neonatal-cord-blood samples. The m.3243A-->G mutation was the most common. No positive calls were seen for five mutations: m.7445A-->G, m.8344A-->G, m.8993T-->G, m.13513G-->A, and m.14459G-->A. In each case, the mutation was confirmed by an independent technique from a fresh aliquot of the source DNA, which was kept in a different laboratory. For the majority of mutations, this was performed with last-cycle fluorescent PCR/RFLP, as described in the Material and Methods section. For m.1555A-->G, the presence of the mutation was confirmed in each case by cloning and sequencing 23 independent clones.
###end p 22
###begin p 23
###xml 296 304 296 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Figure&#160;1</xref>
###xml 643 645 643 645 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sup>
###xml 643 645 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib19" ref-type="bibr"><sup>19</sup></xref>
###xml 647 654 647 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl3" ref-type="table">Table 3</xref>
Twelve subjects harbored a heteroplasmic mtDNA mutation. The mean heteroplasmy level for the 15 positive cases was 43% when homoplasmic mutations were included and 29% when homoplasmic mutations were excluded. The percentage level of mutant mtDNA was evenly distributed above and below the mean (Figure 1). The three homoplasmic subjects, including two known siblings, harbored an LHON mutation. D-loop sequencing and mtDNA haplogroup analysis confirmed that other mutation-positive cases were not maternally related to each other or to known pedigrees from the same geographic region, which had a different mtDNA sequence at two or more sites19 (Table 3).
###end p 23
###begin title 24
Mutations Not Present in Maternal Samples
###end title 24
###begin p 25
No matched maternal sample was available for seven of the positive cases, but in eight cases it was possible to study a maternal blood sample taken at the time of delivery of the offspring. mtDNA mutations were not detectable in the blood of three mothers, with one harboring m.11778G-->A, and two harboring m.3243A-->G. This provides an approximation of the de novo mutation for mtDNA defects at 107/100,000 live births (95% CI = 87-127). Two of the mothers, accounting for the three homoplasmic offspring with LHON mutations, were also homoplasmic for the mtDNA mutation.
###end p 25
###begin title 26
MtDNA Haplogroup Association
###end title 26
###begin p 27
###xml 397 404 395 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl1" ref-type="table">Table 1</xref>
###xml 591 598 583 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl3" ref-type="table">Table 3</xref>
###xml 878 880 870 872 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 878 880 870 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib11" ref-type="bibr"><sup>11</sup></xref>
When the carriers of mtDNA mutations were studied together, the frequency of the major European haplogroups was no different from the background population (Haplogroup H, p = 1.0; J, p = 0.1; U including subgroup K, p = 0.1; T, p = 1). However, all of the m.14484T-->C carriers belonged to haplogroup J (p = 0.011, based on a comparison of the two index cases to the background-population data in Table 1). This was not the case for the other two LHON mutations, m.3460G-->A and m.11778A-->G. Subhaplogroup analysis of the two m.14484T-->C pedigrees on the basis of mtDNA D-loop sequencing (Table 3) showed that one family belonged to J2a (siblings 4607-1 and 0493-1 harbored m.16069T, m.16126C, m.150T, m.152C, m. 195C, m.16145A, and m.16231C) and the other to J1c (02966 harbored m.16069T, m.16126C, m.462T, and m.228A but is wild-type at m.152, m16145, m.16222, and m.16261).11
###end p 27
###begin title 28
Discussion
###end title 28
###begin p 29
###xml 82 85 82 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;6</sup>
###xml 82 85 82 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1 bib2 bib3 bib4 bib5 bib6" ref-type="bibr"><sup>1&#8211;6</sup></xref>
###xml 124 126 124 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">20</sup>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20" ref-type="bibr"><sup>20</sup></xref>
###xml 163 165 163 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">20</sup>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20" ref-type="bibr"><sup>20</sup></xref>
###xml 402 410 402 410 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">15,21,22</sup>
###xml 402 410 402 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib15 bib21 bib22" ref-type="bibr"><sup>15,21,22</sup></xref>
###xml 811 817 785 791 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2,5,23</sup>
###xml 811 817 785 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib2 bib5 bib23" ref-type="bibr"><sup>2,5,23</sup></xref>
Previous studies were based on ascertainment through clinically affected subjects,1-6 were focused on one specific mutation,20 and studied unrelated older subjects20 in whom somatic mutation or mutation loss through segregation are potential confounding factors. We studied randomly ascertained neonatal-cord-blood samples in which the percentage level of mutation is likely to be at its highest level.15,21,22 By studying ten-point mutations in approximately3000 subjects, we detected a pathogenic mtDNA mutation in > 1/200 live births. It is unlikely that the high frequency of mtDNA mutations detected in the general population in this study was due solely to the use of a sensitive technique, because other mutation-specific studies reported a similar level of sensitivity (approximately2-3% for m.3243A-->G2,5,23). It is also unlikely that our positive results were due to crosscontamination, because we confirmed each result using a different method on an independent aliquot of the source DNA, which was kept in another laboratory; we saw no evidence of heteroplasmy on the haplogroup RFLP assays; and, finally, we saw no heteroplasmic nucleotides on the D-loop sequence trace for each positive case. It is conceivable that, in some subjects, we did not detect an mtDNA mutation because the level of heteroplasmy either fell below the sensitivity of our high-throughput screening assay or was at higher percentage levels in other tissues. Our observations, therefore, provide a minimum figure for the prevalence of ten pathogenic mutations and indicate that mtDNA mutations are amongs the most common pathogenic alleles in the general population.
###end p 29
###begin p 30
###xml 194 197 184 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3,6</sup>
###xml 194 197 184 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib3 bib6" ref-type="bibr"><sup>3,6</sup></xref>
###xml 352 354 340 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">20</sup>
###xml 352 354 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20" ref-type="bibr"><sup>20</sup></xref>
###xml 487 488 473 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 487 488 473 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib6" ref-type="bibr"><sup>6</sup></xref>
###xml 945 947 921 923 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sup>
###xml 945 947 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib19" ref-type="bibr"><sup>19</sup></xref>
###xml 1201 1206 1173 1178 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">24,25</sup>
###xml 1201 1206 1173 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib24 bib25" ref-type="bibr"><sup>24,25</sup></xref>
###xml 1370 1372 1342 1344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sup>
###xml 1370 1372 1342 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib10" ref-type="bibr"><sup>10</sup></xref>
###xml 1728 1730 1698 1700 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">26</sup>
###xml 1728 1730 1698 1700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib26" ref-type="bibr"><sup>26</sup></xref>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
Although m.7445A-->G, m.8344A-->G, m.8993T-->G, m.13513G-->A, and m.14459G-->A were not detected, these mutations are also uncommon in mitochondrial-disease patients from the same UK population.3,6 By contrast, the most common heteroplasmic mutation was m.3243A-->G (33%), reaching frequencies similar to that described in one mutation-specific survey.20 m.3243A-->G is also the most common heteroplasmic mtDNA mutation in adults with mtDNA disease from the same geographic region (40%).6 Therefore, a high mutation rate provides the likely explanation for the prevalence of m.3243A-->G in disease cohorts. By contrast, the carrier frequencies of the three major mutations that cause Leber hereditary optic neuropathy (LHON), m.3460G-->A, m.11778G-->A, and m.14484T-->C, were equal. This differs from the distribution for independent families with LHON in the north of England, where the majority of cases harbor the m.11778G-->A mutation (60%).19 All of the asymptomatic m.14484T-->C carriers belonged to mtDNA haplogroup J. This is in keeping with the well-established preferential association between haplogroup J and m.14484T-->C LHON pedigrees ascertained through clinically affected individuals.24,25 However, the data shown here provide the first direct evidence that this association is not due solely to enhanced clinical expression on J, as previously thought.10 Subhaplogroup analysis by mtDNA D-loop sequencing confirmed the independent recurrence of m.14484T-->C in asymptomatic carriers within the population, providing independent evidence that haplogroup J predisposes the mitochondrial genome to mutate at np.14484, possibly through near-neighbor effects as previously described to occur during mtDNA evolution.26
###end p 30
###begin p 31
###xml 169 171 169 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">27</sup>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib27" ref-type="bibr"><sup>27</sup></xref>
###xml 463 471 461 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">15,21,22</sup>
###xml 463 471 461 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib15 bib21 bib22" ref-type="bibr"><sup>15,21,22</sup></xref>
###xml 987 995 983 991 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">15,21,22</sup>
###xml 987 995 983 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib15 bib21 bib22" ref-type="bibr"><sup>15,21,22</sup></xref>
###xml 1080 1082 1076 1078 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">28</sup>
###xml 1080 1082 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib28" ref-type="bibr"><sup>28</sup></xref>
###xml 694 699 <span type="species:ncbi:9606">child</span>
In the heteroplasmic carriers, heteroplasmy levels were evenly distributed above and below the mean, as expected from population-genetic theory based on neutral alleles.27 Of the heteroplasmic offspring with matched maternal samples, the proportion of mutated mtDNA increased with transmission in each case. Although this could be evidence of genetic selection during transmission, the percentage level of m.3243A-->G in blood decreases exponentially during life,15,21,22 so it is highly likely that some of these mothers originally had higher levels of m.3243A-->G, making it difficult to draw firm conclusions. In > 1 in 1000 live births, an mtDNA mutation was present in cord blood from the child but not detectable in the mother's blood, providing an estimation of the de novo mutation rate. It is conceivable that the maternal levels of heteroplasmy were below the detection threshold of the assay, possibly because the level of mutation in blood decreased during the mother's life.15,21,22 However, the level of sensitivity for fluorescent PCR-RFLP is in the region of 1.8%,28 making this unlikely.
###end p 31
###begin p 32
###xml 299 307 297 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">23,29&#8211;31</sup>
###xml 299 307 297 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib23 bib29 bib30 bib31" ref-type="bibr"><sup>23,29&#8211;31</sup></xref>
Detecting heteroplasmic mtDNA mutations in >1 in 200 individuals of the background population has implications for studies reporting mtDNA mutations in specific disease groups. Our data show that putative disease associations, such as the reported high frequency of m.3243A-->G in diabetes mellitus,23,29-31 could be a chance finding irrelevant to pathogenesis. We have identified a massive reservoir of pathogenic mtDNA mutations in the general population, placing greater emphasis on developing techniques to prevent the transmission of pathogenic alleles that could segregate to high levels and thus cause mtDNA diseases in subsequent generations.
###end p 32
###begin title 33
Supplemental Data
###end title 33
###begin p 34
Supplemental data include three tables and can be found with this article online at .
###end p 34
###begin title 35
Supplemental Data
###end title 35
###begin p 36
###xml 0 25 0 25 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="37">Document S1. Three Tables</title>
###xml 0 25 0 25 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="37">Document S1. Three Tables</title></caption>
###xml 25 25 25 25 <media xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="mmc1.pdf" mimetype="application" mime-subtype="pdf"/>
###xml 0 25 0 25 <supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="mmc1"><caption><title textid="37">Document S1. Three Tables</title></caption><media xlink:href="mmc1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material>
Document S1. Three Tables
###end p 36
###begin title 37
Document S1. Three Tables
###end title 37
###begin title 38
Acknowledgments
###end title 38
###begin p 39
This work was principally funded by the United Mitochondrial Diseases Foundation, with additional support from the Association Francaise contre les Myopathies. P.F.C. is a Wellcome Trust Senior Fellow in Clinical Science who also receives funding from the EU FP6 program, EUmitocombat and MITOCIRCLE, the Parkinsons Disease Society (UK), and the Medical Research Council (UK). The authors are grateful for technical assistance from Jocelyn Davies and expert advice given by Simon Pearce and John Burn.
###end p 39
###begin title 40
References
###end title 40
###begin article-title 41
###xml 73 81 <span type="species:ncbi:9606">children</span>
Minimum birth prevalence of mitochondrial respiratory chain disorders in children
###end article-title 41
###begin article-title 42
Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population
###end article-title 42
###begin article-title 43
Epidemiology of pathogenic mitochondrial DNA mutations
###end article-title 43
###begin article-title 44
The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA anbormalities
###end article-title 44
###begin article-title 45
###xml 84 92 <span type="species:ncbi:9606">children</span>
Prevalence, segregation, and phenotype of the mitochondrial DNA 3243A>G mutation in children
###end article-title 45
###begin article-title 46
Prevalence of mitochondrial DNA disease in adults
###end article-title 46
###begin article-title 47
Mitochondrial DNA and the mammalian oocyte
###end article-title 47
###begin article-title 48
###xml 31 36 <span type="species:ncbi:9606">human</span>
Mitochondrial DNA mutations in human disease
###end article-title 48
###begin article-title 49
A reduction in the number of mitochondrial DNA molecules during embryogenesis explains the rapid segregation of genotypes
###end article-title 49
###begin article-title 50
Leber hereditary optic neuropathy: how do mitochondrial DNA mutations cause degeneration of the optic nerve?
###end article-title 50
###begin article-title 51
Haplogroup effects and recombination of mitochondrial DNA: novel clues from the analysis of Leber hereditary optic neuropathy pedigrees
###end article-title 51
###begin article-title 52
The North Cumbria Community Genetics Project
###end article-title 52
###begin article-title 53
DNA repair gene polymorphisms, pre-natal factors and the frequency of somatic mutations in the glycophorin-A gene among healthy newborns
###end article-title 53
###begin article-title 54
Classification of European mtDNAs from an analysis of three European populations
###end article-title 54
###begin article-title 55
Depletion of mitochondrial DNA in leucocytes harbouring the 3243A->G mtDNA mutation
###end article-title 55
###begin article-title 56
###xml 64 69 <span type="species:ncbi:9606">human</span>
Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA
###end article-title 56
###begin article-title 57
The power to detect disease associations with mitochondrial DNA haplogroups
###end article-title 57
###begin article-title 58
Statistical Methods in Medical Research
###end article-title 58
###begin article-title 59
The epidemiology of leber hereditary optic neuropathy in the north East of England
###end article-title 59
###begin article-title 60
Population prevalence of the MELAS A3243G mutation
###end article-title 60
###begin article-title 61
Selection against pathogenic mtDNA mutations in a stem cell population leads to the loss of the 3243A-->G mutation in blood
###end article-title 61
###begin article-title 62
Heteroplasmy levels of a mitochondrial gene mutation associated with diabetes mellitus decrease in leucocyte DNA upon aging
###end article-title 62
###begin article-title 63
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Search for mitochondrial DNA mutation at position 3243 in German patients with a positive family history of maternal diabetes mellitus
###end article-title 63
###begin article-title 64
Haplotype and phylogenetic analyses suggest that one European-specific mtDNA background plays a role in the expression of Leber hereditary optic neuropathy by increasing the penetrance of the primary mutations 11778 and 14484
###end article-title 64
###begin article-title 65
Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background
###end article-title 65
###begin article-title 66
###xml 36 41 <span type="species:ncbi:9606">human</span>
A compositional segmentation of the human mitochondrial genome is related to heterogeneities in the guanine mutation rate
###end article-title 66
###begin article-title 67
Solution of a Process of Random Genetic Drift with a Continuous Model
###end article-title 67
###begin article-title 68
Episodic ataxia and hemiplegia caused by the 8993T->C mitochondrial DNA mutation
###end article-title 68
###begin article-title 69
Prevalence and clinical characterisation of Japanese diabetes mellitus with an A-to-G mutation at nucleotide 3243 of the mitochondrial tRNALeu(UUR) gene
###end article-title 69
###begin article-title 70
Maternally inherited diabetes and deafness: prevalence in a hospital diabetic population
###end article-title 70
###begin article-title 71
###xml 123 131 <span type="species:ncbi:9606">patients</span>
Prevalence and clinical characteristics of mitochondrial tRNAleu(UUR) nt 3243 A-->G and nt 3316 G-->A mutations in Chinese patients with type 2 diabetes
###end article-title 71
###begin p 72
Percentage of Mutated mtDNA in the 15 Mutation-Positive Cases
###end p 72
###begin p 73
Red: m.14484T-->C; blue: m.11778G-->A; green: m.3460G-->A; black: m.3243A-->G; orange: m.1555A-->G.
###end p 73
###begin p 74
mtDNA Haplogroup Distribution in 344 Random Umbilical-Cord-Blood Samples from North Cumbria, England
###end p 74
###begin p 75
95% CI = Exact 95% confidence interval. The haplogroup U data includes the K subgroup. There were 27 subjects who belonged to the K subgroup of haplogroup U (K = 7.85% of the entire control cohort, 95% CI = 5.24-11.21).
###end p 75
###begin p 76
The Frequency of Ten Pathogenic mtDNA Mutations in North Cumbria, England
###end p 76
###begin p 77
For nine mutations, the percentage of mutated mtDNA was determined by last-cycle fluorescent PCR. For m.1555A-->G, heteroplasmy was quantified by cloning and sequencing of independent mtDNA fragments. The detection threshold for the m.1555A-->G mutation could not be quantified because of a lack of an efficient fluorescent RFLP assay. However, dilution curves similar to those demonstrated estimated the assay to be efficient in detecting low levels of heteroplasmy. Quantification by cloning and sequencing of mtDNA fragments of the lowest dilution positively identified by MALDI-TOF MS indicated that the threshold of detection for m.1555A-->G was 1.4% (1 of 70 independent clones).
###end p 77
###begin p 78
Two of these three subjects were known to be siblings. CI denotes confidence interval.
###end p 78
###begin p 79
MtDNA haplogroup refers to the individual positive cases and their associated mtDNA haplogroup. The number is the case identifier; the letter refers to the European mtDNA haplogroup. K indicates the K subgroup of haplogroup U.
###end p 79
###begin p 80
mtDNA D-Loop Sequence for the Mutation-Positive Cases
###end p 80
###begin p 81
###xml 88 90 88 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">16</sup>
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib16" ref-type="bibr"><sup>16</sup></xref>
rCRS indicates nucleotide present in the revised Cambridge reference sequence for mtDNA.16
###end p 81
###begin p 82
np indicates "nucleotide pair," numbered according to the rCRS.
###end p 82
###begin p 83
Dashes indicate rCRS nucleotides.
###end p 83
###begin p 84
Matched maternal samples.
###end p 84

